HUYABIO International, LLC.

Quick facts

Phase 3 pipeline

• HBI-8000 in combination with nivolumab · Oncology
  HBI-8000 is a histone deacetylase (HDAC) inhibitor that enhances immune response when combined with nivolumab, a PD-1 checkpoint inhibitor.
• Placebo in combination with nivolumab · Oncology
  Nivolumab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• HUYABIO International, LLC. portfolio CI brief
• HUYABIO International, LLC. pipeline updates RSS